On the one hand, breast cancers evolved resistance mechanisms, such as RB1 inactivation or ESR1 gain-of-function changes, to deregulate cell cycle control and drive aggressive cell growth and proliferation. This evidence concerns the gene ESR1 and breast carcinoma.